# A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

> **NCT03499223** · PHASE2 · COMPLETED · sponsor: **Oxurion** · enrollment: 70 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** Ranibizumab 0.5mg
- **DRUG:** THR-317 8mg
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT03499223
- **Lead sponsor:** Oxurion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-20
- **Primary completion:** 2019-07-18
- **Final completion:** 2019-07-18
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499223, "A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03499223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*